自身免疫性疱病的表位扩展现象

doi:10.35541/cjd.20201019

Abstract

Abstract: 【Abstract】 Epitope spreading often occurs in patients with autoimmune bullous diseases （ABDs）, resulting in exposure of more antigenic epitopes, aggravation or transformation of pre-existing diseases, or concurrence of other diseases. With the increase in the immunological evidence for epitope spreading, more and more scholars have realized that epitope spreading plays an important role in the development of ABDs. This review introduces the phenomenon of epitope spreading in ABDs from 4 aspects, including the concurrence or transformation between different types of pemphigoid, different types of pemphigus, pemphigus and pemphigoid, as well as between ABDs and other skin diseases.

Key words: Pemphigoid, bullous, Pemphigus, Epitopes, Autoimmune bullous diseases, Epitope spreading, psoriasis

Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases[J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705.doi:10.35541/cjd.20201019

References ［33］

［1］	铁·杜尔娜, 左亚刚. 类天疱疮致病性抗体与免疫吸附［J］. 临床皮肤科杂志, 2015,44（4）:264⁃267. doi: 10.16761/j.cnki.1000⁃4963.2015.04.036.
［2］	Ujiie H, Yoshimoto N, Natsuga K, et al. Immune reaction to type XVII collagen induces intramolecular and intermolecular epitope spreading in experimental bullous pemphigoid models［J］. Front Immunol, 2019,10:1410. doi: 10.3389/fimmu.2019. 01410.
［3］	Hashimoto T, Tsuruta D, Dainichi T, et al. Demonstration of epitope spreading in bullous pemphigoid: results of a prospective multicenter study［J］. J Invest Dermatol, 2011,131（11）:2175⁃2177. doi: 10.1038/jid.2011.276.
［4］	Seo T, Ujiie H, Ujiie I, et al. Epitope spreading possibly from BP230 to the NC16A domain of BP180 preceding disease progression in bullous pemphigoid［J］. J Dermatol, 2020,47（7）:e255⁃e257. doi: 10.1111/1346⁃8138.15362.
［5］	Didona D, Di Zenzo G. Humoral epitope spreading in autoimmune bullous diseases［J］. Front Immunol, 2018,9:779. doi: 10.3389/fimmu.2018.00779.
［6］	Fairley JA, Woodley DT, Chen M, et al. A patient with both bullous pemphigoid and epidermolysis bullosa acquisita: an example of intermolecular epitope spreading［J］. J Am Acad Dermatol, 2004,51（1）:118⁃122. doi: 10.1016/j.jaad.2003.12.033.
［7］	Kasperkiewicz M, Hoppe U, Zillikens D, et al. Relapse⁃associated autoantibodies to BP180 in a patient with anti⁃p200 pemphigoid［J］. Clin Exp Dermatol, 2010,35（6）:614⁃617. doi: 10.1111/j.1365⁃2230.2009.03731.x.
［8］	Li Y, Foshee JB, Sontheimer RD. Sustained clinical response to rituximab in a case of life⁃threatening overlap subepidermal autoimmune blistering disease［J］. J Am Acad Dermatol, 2011, 64（4）: 773⁃778. doi: 10.1016/j.jaad.2009.09.045.
［9］	Wald A, Schmidt E, Toberer F, et al. Overlap of bullous, anti⁃laminin⁃332, and anti⁃p200 pemphigoid with concomitant anti⁃contactin⁃1⁃positive inflammatory polyneuropathy treated with intravenous immunoglobulins as a manifestation of epitope spreading［J］. JAMA Dermatol, 2019,155（5）:631⁃633. doi: 10. 1001/jamadermatol.2018.5536.
［10］	Hasegawa A, Shinkuma S, Katsumi T, et al. Localized bullous pemphigoid recurring at different sites: two case reports［J］. Eur J Dermatol, 2020. doi: 10.1684/ejd.2019.3672.
［11］	Zhou S, Zou Y, Pan M. Brunsting⁃Perry pemphigoid transitioning from previous bullous pemphigoid［J］. JAAD Case Rep, 2020,6（3）:192⁃194. doi: 10.1016/j.jdcr.2019.12.018.
［12］	Takama H, Yoshida M, Izumi K, et al. Dipeptidyl peptidase⁃4 Inhibitor⁃associated bullous pemphigoid: recurrence with epitope spreading ［J］. Acta Derm Venereol, 2018,98（10）:983⁃984. doi: 10.2340/00015555⁃3010.
［13］	García⁃Díez I, España A, Iranzo P. Epitope⁃spreading phenomena in dipeptidyl peptidase⁃4 inhibitor⁃associated bullous pemphigoid［J］. Br J Dermatol, 2019, 180（5）: 1267⁃1268. doi: 10.1111/bjd.17690.
［14］	Kodera R, Chiba Y, Tamura Y, et al. Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: the association with the use of dipeptidyl peptidase⁃4 inhibitors［J］. Nihon Ronen Igakkai Zasshi, 2019,56（1）:43⁃50. doi: 10.3143/geriatrics.56.43.
［15］	Giusti D, Gatouillat G, Le Jan S, et al. Anti⁃type VII collagen antibodies are identified in a subpopulation of bullous pemphigoid patients with relapse［J］. Front Immunol, 2018, 9:570. doi: 10.3389/fimmu.2018.00570.
［16］	Komai A, Amagai M, Ishii K, et al. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme⁃linked immunosorbent assay［J］. Br J Dermatol, 2001, 144（6）: 1177⁃1182. doi: 10.1046/j.1365⁃2133.2001.04227.x.
［17］	Chapman CM, Kwock J, Cresce N, et al. IgG/IgA pemphigus in a patient with a history of pemphigus vulgaris: an example of epitope spreading?［J］. J Cutan Pathol, 2019,46（5）:380⁃382. doi: 10.1111/cup.13433.
［18］	Tóth GG, Pas HH, Jonkman MF. Transition of pemphigus vulgaris into pemphigus foliaceus confirmed by antidesmoglein ELISA profile［J］. Int J Dermatol, 2002,41（8）:525⁃527. doi: 10. 1046/j.1365⁃4362.2002.15452.x.
［19］	Okahashi K, Oiso N, Ishii N, et al. Paraneoplastic pemphigus associated with Castleman disease: progression from mucous to mucocutaneous lesions with epitope⁃spreading phenomena［J］. Br J Dermatol, 2017,176（5）:1406⁃1409. doi: 10.1111/bjd.15389.
［20］	Recke A, Rose C, Schmidt E, et al. Transition from pemphigus foliaceus to bullous pemphigoid: intermolecular B⁃cell epitope spreading without IgG subclass shifting［J］. J Am Acad Dermatol, 2009, 61（2）: 333⁃336. doi: 10.1016/j.jaad.2008.10.061.
［21］	Peterson JD, Chang AJ, Chan LS. Clinical evidence of an intermolecular epitope spreading in a patient with pemphigus foliaceus converting into bullous pemphigoid［J］. Arch Dermatol, 2007,143（2）:272⁃274. doi: 10.1001/archderm.143.2.272.
［22］	Schauer F, Steinke H, Thoma K, et al. Transition from bullous pemphigoid to pemphigus foliaceus: intermolecular epitope spreading thirteen years after initial diagnosis［J］. Acta Derm Venereol, 2019, 99（11）: 1029⁃1030. doi: 10.2340/00015555⁃3250.
［23］	Sárdy M, Borovaya A, Horváth ON, et al. Successful rituximab treatment of juvenile bullous pemphigoid with esophageal scarring due to epitope spreading［J］. J Dtsch Dermatol Ges, 2016, 14（6）: 618⁃621. doi: 10.1111/ddg.12902.
［24］	Koga H, Ishii N, Hashimoto T, et al. Case of shift from linear immunoglobulin A bullous dermatosis to pemphigus herpetiformis for a short period of time［J］. J Dermatol, 2017,44（2）:189⁃193. doi: 10.1111/1346⁃8138.13677.
［25］	Boh E, Roberts LJ, Lieu TS, et al. Epidermolysis bullosa acquisita preceding the development of systemic lupus erythematosus［J］. J Am Acad Dermatol, 1990,22（4）:587⁃593. doi: 10.1016/0190⁃9622（90）70077⁃u.
［26］	Moon SY, Eun DH, Jung HJ, et al. Coexistence of psoriasis and epidermolysis bullosa acquisita: evaluation of the integrity of the basement membrane［J］. J Cutan Pathol, 2017,44（6）:602⁃603. doi: 10.1111/cup.12940.
［27］	Krishnaswamy K, Raju BP, Raveendra L. Epitope spreading phenomenon: a case report［J］. Indian Dermatol Online J, 2019,10（5）:580⁃584. doi: 10.4103/idoj.IDOJ_416_18.
［28］	Zheng J, Liu N, Wang Y, et al. Pemphigus vulgaris with psoriasis vulgaris successfully treated with methotrexate and low⁃dose methylprednisolone ［J］. Dermatol Ther, 2020,33（1）:e13165. doi: 10.1111/dth.13165.
［29］	Balighi K, Daneshpazhooh M, Mahmoudi H, et al. Switching from pemphigus vulgaris to psoriasis: a rare report of three cases ［J］. Int J Dermatol, 2020,59（5）:e144⁃e146. doi: 10.1111/ijd. 14823.
［30］	Mignogna MD, Fortuna G, Leuci S, et al. Lichen planus pemphigoides, a possible example of epitope spreading［J］. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010,109（6）:837⁃843. doi: 10.1016/j.tripleo.2009.12.044.
［31］	Reis Gavazzoni Dias MF, Aparecida Guedes Vilar E, de Oliveira Bento C, et al. Brunsting⁃Perry type pemphigoid causing secondary cicatricial alopecia in 2 patients［J］. Skin Appendage Disord , 2018,4（4）:308⁃311. doi: 10.1159/000485570.
［32］	Huff SB, Vasu S, Kaffenberger BH. Epitope spread in chronic mucosal GVHD: mucous membrane pemphigoid resolution with rituximab［J］. Int J Dermatol, 2019,58（2）:240⁃241. doi: 10.1111/ ijd.14027.
［33］	Azizpour A, Nasimi M, Shakoei S, et al. Bullous pemphigoid induced by Hijama therapy （cupping）［J］. Dermatol Pract Concept, 2018,8（3）:163⁃165. doi: 10.5826/dpc.0803a01.

[1]	Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692.
[2]	Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650.
[3]	Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[4]	China Dermatologist Association, Chinese Society of Dermatology, Xijing Hospital, Air Force Medical University, Chinese Dietary Guideline for Psoriasis Patients Task Force. Dietary guideline for patients with psoriasis in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 389-401.
[5]	Sun Yujiao, Wang Jianbo, Duan Ziyu, Dou Jinfa, Li Yan, Li Jianguo, Zhang Shoumin. Detection of ATP2C1 gene mutations in a family with generalized familial benign chronic pemphigus [J]. Chinese Journal of Dermatology, 2023, 56(4): 335-337.
[6]	Lian Panpan, Liu Jun, Su Zhonglan, Wang Hongwei. Effect of peroxisome proliferator-activated receptor γ on skin physiological and pathological processes [J]. Chinese Journal of Dermatology, 2023, 56(4): 365-368.
[7]	Jin Liping, Zhu Wu, Lu Yan, Liu Panpan, Tan Minjia, Wang Ying, Yang Jing, Xu Licong, Hu Kun, Kuang Yehong. Dietary intervention for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(4): 357-360.
[8]	Ruan Shifan, Zhang Peng, Lin Tingting, Luo Renwei, Bao Siyi, Xue Chenyao, Tong Zequn, Zhang Liangliang, Gong Ting, Ji Chao, . Correlations between psoriasis vulgaris and dyslipidemia [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220322-e20220322.
[9]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[10]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[11]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[12]	Wan Li, Hu Bin, Luo Hongyu, Fang Meizhen, Han Lijuan, Chen Qiang, Zhou Xiaoyong, Chen Liuqing, Chen Jinbo. Clinical characteristics and treatment of eight cases of pemphigus/bullous pemphigoid complicated by herpes simplex virus infection [J]. Chinese Journal of Dermatology, 2023, 56(3): 229-233.
[13]	Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 0(3): 20210794-e20210794.
[14]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[15]	Yang Qi, Zheng Jie. Effect of biologics on cardiovascular comorbidities of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 165-169.

Epitope spreading in autoimmune bullous diseases

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［33］

Related Articles 15

Metrics

Comments

Recommended 10